Navigation Links
Gentris Corporation Launches New Pharmacogenomics Services
Date:7/12/2012

MORRISVILLE, N.C., July 12, 2012 /PRNewswire/ -- Gentris Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository services, announced today that it has expanded its genomic biomarker services by incorporating multiple technology platforms into its 24,000 sq. ft., CLIA-certified, GLP-compliant laboratory. Gentris has integrated the Affymetrix GCS3000, Sequenom MassArray, and LifeTech Ion Torrent technologies in a continued effort to identify polymorphisms involved in drug response and adverse drug events as well as in determining somatic mutations in cancer.  

Gentris has utilized Affymetrix DMET™ Plus analysis in a number of clinical studies, including oncology clinical trials. DMET™ Plus analysis allows drug developers to understand how variations in drug metabolism enzymes and drug transporters between patients affects adverse drug responses and treatment efficacy. This type of analysis has been implemented by major pharmaceutical companies in Phase I through Phase III clinical trials focused on numerous therapeutic areas.  Most recently, Gentris collaborated with Dr. Howard McLeod of UNC-Chapel Hill to assess the risk of sensory neuropathy in breast cancer patients with genetic variations in drug metabolizing enzymes.

With the integration of Sequenom's MassArray, Gentris is able to design customizable, multiplex panels of genes for use in clinical trials.  The Company has already designed a custom panel for a top ten pharmaceutical company.  In addition, Gentris offers the iPLEX ADME PGx panel, which examines 192 of the most common variants in 36 ADME genes; the OncoCarta Panel v1.0, which is a comprehensive screen of 19 oncogenes and 238 mutations; and the Sequenom Sample ID Plus panel, which ensures that chain of custody is maintained and that there is amplifiable DNA in the sample.

The latest platform to be brought online is LifeTech's Ion Torrent Personal Genome Machine (PGM) for next generation sequencing. The Ion Torrent PGM allows for rapid, deep sequencing of large areas of the genome, which can efficiently identify both common and rare variations that may better predict the safety and efficacy of new drugs in development. Currently, Gentris is using the Ion Torrent PGM for discovery initiatives with its pharmaceutical partners as well as part of a collaboration with UNC-Chapel Hill. 

Related Links: www.gentris.com

Quotes:

"The expansion of our services by using these platform technologies allows us to provide our clients quality and regulated services in all phases of the clinical development pipeline," said Dr. L.Scott Clark, Gentris Chief Scientific Officer. "It's very exciting to use the Ion Torrent for discovery initiatives, because the depth of coverage and resolution can reveal new SNPs and variations that may be clinically relevant. However, these results need to be verified on a second platform which Gentris can perform because of its extensive experience with real-time PCR, Sanger sequencing, and Sequenom platforms."  

"The key to successfully implementing pharmacogenomics is to use the right platform to answer your specific question," said Dr. Howard McLeod, Director of the UNC Institute for Pharmacogenomics and Individualized Therapy and Gentris Chief Scientific Advisor. "By integrating multiple platforms, Gentris has the ability to address the needs of pharmaceutical clients during any stage in the clinical development of a drug. I'm excited to be working with them to discover, translate, and validate new biomarkers that will have an impact on patient care."

About Gentris Corporation:

Founded in 2001, Gentris is located in Research Triangle Park, NC, where it provides pharmacogenomics and biorepository support for all phases of clinical studies and genomic biomarker programs.  The Company works with academic and industry leaders to translate innovations in pharmacogenomics into safer, more effective medicines, which can lead to accelerated drug development and improvement in patient care globally.




'/>"/>
SOURCE Gentris Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Gentris Corporation Partners with the Shanghai Institutes of Preventative Medicine
2. BioElectronics Corporation Announces Initiative for UK and German Markets
3. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
4. Luminex Corporation Announces Agreement to Acquire GenturaDx
5. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
6. BioElectronics Corporation Announces Indian Distributors Ecommerce Website
7. Celladon Corporation Receives Notice of Allowance from European Patent Office
8. FMC Corporation Acquires Phytone, Ltd., a Leading European Natural Colors Business
9. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
10. Centene Corporation Selected for Ohio Medicaid Contract
11. Premier healthcare alliance honors Atrium Medical Corporation for operational excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global Wound ... report to their offering. ... The global wound care market was worth $24,482.9 million in 2015 and ... Among the various wound care products type, the advanced wound ... 2015. Among the various applications, surgical wound segment held the largest share ...
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... , March 24, 2017 FinancialBuzz.com News Commentary ... Medical cannabis products around ... Research, Inc., projects that the global medical cannabis market will reach a ... is a major market for the new growing industry. By the ... to legally buy and sell medical cannabis. More conservative states like ...
Breaking Medicine Technology:
(Date:3/27/2017)... Fla. (PRWEB) , ... March 27, 2017 , ... ... overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 of the ... McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax on prescription ...
(Date:3/25/2017)... ... ... Norland at Swissray is pleased to announce the release of the ELITE DXA, ... has an active scan window, which is more than double that of existing bone densitometers. ... could not undergo an accurate total body bone density or body composition study. ...
(Date:3/24/2017)... Greenville, SC (PRWEB) , ... March 24, 2017 , ... ... , is excited to announce the opening of a Greenville, South Carolina ... center for digital progress in Greenville. , “We’ve been working with South Carolina clients ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... planning, and related services to families and business owners across eastern Michigan, is ... feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry ...
(Date:3/24/2017)... CA (PRWEB) , ... March 24, 2017 , ... ... on two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, ... Creating the Administrative Record, The majority of cases litigated under ERISA involve claims ...
Breaking Medicine News(10 mins):